Galmed Pharmaceuticals Files 6-K Report
Ticker: GLMD · Form: 6-K · Filed: Apr 14, 2026
Sentiment: neutral
Topics: disclosure, foreign-issuer
TL;DR
Galmed Pharma filed a 6-K on 4/14/26. Standard disclosure.
AI Summary
Galmed Pharmaceuticals Ltd. filed a 6-K report on April 14, 2026. The filing includes a 6-K form and an exhibit EX-99.1. The company's mailing and business addresses are listed as C/O MEITAR LAW OFFICES in Ramat Gan, Israel.
Why It Matters
This filing provides routine corporate updates and disclosures for Galmed Pharmaceuticals Ltd., a foreign issuer, as required by SEC regulations.
Risk Assessment
Risk Level: low — This is a routine 6-K filing, which typically contains standard corporate disclosures and does not involve significant new financial or operational information.
Key Players & Entities
- Galmed Pharmaceuticals Ltd. (company) — Filer
- MEITAR LAW OFFICES (company) — Mailing and Business Address
FAQ
What type of SEC filing is this?
This is a Form 6-K, which is a report of a foreign issuer.
When was this filing accepted by the SEC?
The filing was accepted on April 14, 2026, at 07:42:10.
What are the listed addresses for Galmed Pharmaceuticals Ltd.?
The mailing and business addresses are both listed as C/O MEITAR LAW OFFICES, 16 ABBA HILLEL SILVER RD., RAMAT GAN L3 5250608.
What is the CIK number for Galmed Pharmaceuticals Ltd.?
The CIK number for Galmed Pharmaceuticals Ltd. is 0001595353.
What are the included documents in this filing?
The filing includes a 6-K form (form6-k.htm) and an exhibit EX-99.1 (ex99-1.htm).
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 14, 2026 regarding Galmed Pharmaceuticals Ltd. (GLMD).